CA2318902A1 - Pharmaceutical composition comprising vanadium and/or salts thereof and its use to treat burns - Google Patents
Pharmaceutical composition comprising vanadium and/or salts thereof and its use to treat burns Download PDFInfo
- Publication number
- CA2318902A1 CA2318902A1 CA002318902A CA2318902A CA2318902A1 CA 2318902 A1 CA2318902 A1 CA 2318902A1 CA 002318902 A CA002318902 A CA 002318902A CA 2318902 A CA2318902 A CA 2318902A CA 2318902 A1 CA2318902 A1 CA 2318902A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- growth
- vanadium
- composition according
- pyoverdine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052720 vanadium Inorganic materials 0.000 title claims abstract description 52
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 150000003839 salts Chemical class 0.000 title claims abstract description 21
- 230000001580 bacterial effect Effects 0.000 claims abstract description 19
- 230000007704 transition Effects 0.000 claims abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 241000589516 Pseudomonas Species 0.000 claims abstract description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 64
- 108010025281 pyoverdin Proteins 0.000 claims description 54
- 229910052742 iron Inorganic materials 0.000 claims description 29
- 241000894006 Bacteria Species 0.000 claims description 16
- 239000000589 Siderophore Substances 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 208000001388 Opportunistic Infections Diseases 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 241000222122 Candida albicans Species 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 201000007336 Cryptococcosis Diseases 0.000 claims description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 2
- 241000228402 Histoplasma Species 0.000 claims description 2
- 241000228404 Histoplasma capsulatum Species 0.000 claims description 2
- 241000223252 Rhodotorula Species 0.000 claims description 2
- 241000223254 Rhodotorula mucilaginosa Species 0.000 claims description 2
- 241000122971 Stenotrophomonas Species 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 230000000063 preceeding effect Effects 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 150000003681 vanadium Chemical class 0.000 abstract description 5
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 208000008960 Diabetic foot Diseases 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 11
- PZZHMLOHNYWKIK-UHFFFAOYSA-N eddha Chemical compound C=1C=CC=C(O)C=1C(C(=O)O)NCCNC(C(O)=O)C1=CC=CC=C1O PZZHMLOHNYWKIK-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000009036 growth inhibition Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 5
- 101150026476 PAO1 gene Proteins 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- NYBZAGXTZXPYND-GBIKHYSHSA-N pyochelin I Chemical compound S1C[C@@H](C(O)=O)N(C)[C@H]1[C@@H]1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-GBIKHYSHSA-N 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003682 vanadium compounds Chemical class 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NYBZAGXTZXPYND-UHFFFAOYSA-N Pyochelin I Natural products S1CC(C(O)=O)N(C)C1C1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 125000005287 vanadyl group Chemical group 0.000 description 2
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 2
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 2
- 229940041260 vanadyl sulfate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- VJNMUKGZDONIAN-UHFFFAOYSA-N 1-methylisoquinolin-6-amine Chemical compound NC1=CC=C2C(C)=NC=CC2=C1 VJNMUKGZDONIAN-UHFFFAOYSA-N 0.000 description 1
- 101000891166 Aeromonas hydrophila Putative isochorismate synthase Proteins 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SERBHKJMVBATSJ-UHFFFAOYSA-N Enterobactin Natural products OC1=CC=CC(C(=O)NC2C(OCC(C(=O)OCC(C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-UHFFFAOYSA-N 0.000 description 1
- 108010061075 Enterobactin Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
- KDHHWXGBNUCREU-HOTGVXAUSA-N Ferric-aerobactin Chemical compound CC(=O)N(O)CCCC[C@@H](C(O)=O)NC(=O)CC(O)(C(O)=O)CC(=O)N[C@H](C(O)=O)CCCCN(O)C(C)=O KDHHWXGBNUCREU-HOTGVXAUSA-N 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001440871 Neisseria sp. Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000960597 Pseudomonas fluorescens group Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- QUEDYRXQWSDKKG-UHFFFAOYSA-M [O-2].[O-2].[V+5].[OH-] Chemical compound [O-2].[O-2].[V+5].[OH-] QUEDYRXQWSDKKG-UHFFFAOYSA-M 0.000 description 1
- IBJKCMMJJCJCLT-UHFFFAOYSA-M [S-2].[S-2].[SH-].[V+5] Chemical compound [S-2].[S-2].[SH-].[V+5] IBJKCMMJJCJCLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 244000000007 bacterial human pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical class OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GSOLWAFGMNOBSY-UHFFFAOYSA-N cobalt Chemical compound [Co][Co][Co][Co][Co][Co][Co][Co] GSOLWAFGMNOBSY-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- SERBHKJMVBATSJ-BZSNNMDCSA-N enterobactin Chemical compound OC1=CC=CC(C(=O)N[C@@H]2C(OC[C@@H](C(=O)OC[C@@H](C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-BZSNNMDCSA-N 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- QLOKAVKWGPPUCM-UHFFFAOYSA-N oxovanadium;dihydrochloride Chemical compound Cl.Cl.[V]=O QLOKAVKWGPPUCM-UHFFFAOYSA-N 0.000 description 1
- NFVUDQKTAWONMJ-UHFFFAOYSA-I pentafluorovanadium Chemical compound [F-].[F-].[F-].[F-].[F-].[V+5] NFVUDQKTAWONMJ-UHFFFAOYSA-I 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003549 thiazolines Chemical class 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- JTWLHYPUICYOLE-UHFFFAOYSA-J vanadium tetrafluoride Chemical compound [F-].[F-].[F-].[F-].[V+4] JTWLHYPUICYOLE-UHFFFAOYSA-J 0.000 description 1
- 229910000351 vanadium(III) sulfate Inorganic materials 0.000 description 1
- OYCGXLKTCYDJNJ-UHFFFAOYSA-H vanadium;trisulfate Chemical compound [V].[V].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OYCGXLKTCYDJNJ-UHFFFAOYSA-H 0.000 description 1
- LLMKLMMXMOTPRU-YOAXHERRSA-N vibriobactin Chemical compound O=C([C@@H]1N=C(O[C@H]1C)C=1C(=C(O)C=CC=1)O)NCCCN(C(=O)[C@@H]1[C@H](OC(=N1)C=1C(=C(O)C=CC=1)O)C)CCCNC(=O)C1=CC=CC(O)=C1O LLMKLMMXMOTPRU-YOAXHERRSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98200223 | 1998-01-27 | ||
| EP98200223.0 | 1998-01-27 | ||
| PCT/EP1999/000483 WO1999037312A1 (en) | 1998-01-27 | 1999-01-26 | Pharmaceutical composition comprising vanadium and/or salts thereof and its use to treat burns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2318902A1 true CA2318902A1 (en) | 1999-07-29 |
Family
ID=8233324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002318902A Abandoned CA2318902A1 (en) | 1998-01-27 | 1999-01-26 | Pharmaceutical composition comprising vanadium and/or salts thereof and its use to treat burns |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1051184A1 (de) |
| AU (1) | AU2719299A (de) |
| CA (1) | CA2318902A1 (de) |
| WO (1) | WO1999037312A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040943A1 (it) * | 2004-05-11 | 2004-08-11 | Icim Internat S R L | Composizione farmaceutica cicatrizzante |
| WO2011160444A1 (zh) * | 2010-06-24 | 2011-12-29 | 攀枝花东方微元科技有限公司 | 含钒的药物组合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3929411A1 (de) * | 1988-09-22 | 1990-03-29 | Siegfried Natterer | Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung |
| RU2078570C1 (ru) * | 1993-01-11 | 1997-05-10 | Галина Юрьевна Рыльникова | Средство для энтеросорбции при термических ожогах |
-
1999
- 1999-01-26 WO PCT/EP1999/000483 patent/WO1999037312A1/en not_active Ceased
- 1999-01-26 EP EP99907421A patent/EP1051184A1/de not_active Withdrawn
- 1999-01-26 AU AU27192/99A patent/AU2719299A/en not_active Abandoned
- 1999-01-26 CA CA002318902A patent/CA2318902A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1051184A1 (de) | 2000-11-15 |
| AU2719299A (en) | 1999-08-09 |
| WO1999037312A1 (en) | 1999-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6509948B2 (ja) | 抗菌組成物 | |
| Spacciapoli et al. | Antimicrobial activity of silver nitrate against periodontal pathogens | |
| US8343911B2 (en) | Methods of inhibiting and treating bacterial biofilms by metal chelators | |
| AU2007230597B2 (en) | Antimicrobial composition | |
| US6042848A (en) | Enhancement of antimicrobial peptide activity by metal ions | |
| Singh et al. | Antibacterial activities of bacteriagenic silver nanoparticles against nosocomial Acinetobacter baumannii | |
| JP2009114206A (ja) | 抗微生物活性を有する医薬組成物 | |
| US20100068297A1 (en) | Antimicrobial Composition | |
| WO2012167368A1 (en) | Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism | |
| US20250114398A1 (en) | Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof | |
| US20110245148A1 (en) | Acetic acid and a buffer | |
| CA2318902A1 (en) | Pharmaceutical composition comprising vanadium and/or salts thereof and its use to treat burns | |
| EP3576730A1 (de) | Antimikrobielle zusammensetzungen mit kupferhydroxypyronkomplexen | |
| Roberts | Antimicrobial agents used in wound care | |
| Andersen et al. | Pivmecillinam in the treatment of therapy resistant urinary tract infections: A comparison with pivmecillinam, pivampicillin and their combination | |
| Hales et al. | The effect of a range of antimicrobial drugs on the haemagglutination of two clinical isolates from urinary tract infections | |
| CN121693334A (zh) | 用于预防和/或治疗病毒和细菌感染的鼻内组合物 | |
| GB2292884A (en) | Rifamycin & bismuth salts for treating bacterial infections | |
| Ray et al. | Chemotherapeutic Activity of Bluensomycin | |
| Mujeeb et al. | COMPARATIVE STUDY OF EFFICACY OF DIFFERENT TOPICAL AGENTS FOR CONTROLLING WOUND INFECTIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |